Candriam S.C.A. Buys 213,448 Shares of Xylem Inc. $XYL

Candriam S.C.A. boosted its position in Xylem Inc. (NYSE:XYL) by 28.0% during the first quarter, Holdings Channel.com reports. The fund owned 974,871 shares of the industrial products company’s stock after acquiring an additional 213,448 shares during the period. Candriam S.C.A.’s holdings in Xylem were worth $116,497,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Callahan Advisors LLC purchased a new stake in Xylem in the fourth quarter worth about $1,721,000. Northwestern Mutual Wealth Management Co. grew its stake in shares of Xylem by 2,309.7% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 431,824 shares of the industrial products company’s stock worth $54,314,000 after buying an additional 413,904 shares during the last quarter. Abacus Wealth Partners LLC bought a new position in Xylem during the 4th quarter valued at approximately $1,663,000. Boston Common Asset Management LLC boosted its holdings in Xylem by 15.3% in the fourth quarter. Boston Common Asset Management LLC now owns 143,740 shares of the industrial products company’s stock worth $19,575,000 after acquiring an additional 19,073 shares in the last quarter. Finally, Norges Bank purchased a new stake in shares of Xylem in the fourth quarter worth $361,012,000. 87.96% of the stock is owned by institutional investors.

Xylem Stock Up 2.0%

NYSE:XYL opened at $121.26 on Friday. The company has a 50-day moving average of $112.64 and a 200 day moving average of $124.05. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.46 and a quick ratio of 1.10. The firm has a market cap of $28.82 billion, a PE ratio of 30.16, a price-to-earnings-growth ratio of 1.69 and a beta of 1.03. Xylem Inc. has a 1-year low of $105.29 and a 1-year high of $154.27.

Xylem (NYSE:XYL) last released its quarterly earnings results on Tuesday, April 28th. The industrial products company reported $1.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.09 by $0.03. The business had revenue of $2.12 billion for the quarter, compared to analyst estimates of $2.11 billion. Xylem had a net margin of 10.79% and a return on equity of 11.26%. The business’s revenue for the quarter was up 2.7% on a year-over-year basis. During the same period in the previous year, the company earned $1.03 earnings per share. Xylem has set its FY 2026 guidance at 5.350-5.600 EPS. As a group, research analysts anticipate that Xylem Inc. will post 5.51 EPS for the current fiscal year.

Xylem Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, June 25th. Investors of record on Thursday, May 28th were given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 1.4%. The ex-dividend date was Thursday, May 28th. Xylem’s dividend payout ratio (DPR) is currently 42.79%.

Insider Activity at Xylem

In other news, Director Jerome A. Peribere purchased 1,210 shares of the stock in a transaction that occurred on Monday, May 4th. The shares were purchased at an average cost of $116.61 per share, with a total value of $141,098.10. Following the completion of the acquisition, the director owned 27,209 shares of the company’s stock, valued at approximately $3,172,841.49. This represents a 4.65% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Geri-Michelle Mcshane sold 4,269 shares of the stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $117.46, for a total value of $501,436.74. Following the transaction, the chief accounting officer owned 3,605 shares in the company, valued at $423,443.30. This represents a 54.22% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 0.32% of the company’s stock.

Analyst Ratings Changes

Several brokerages have issued reports on XYL. Weiss Ratings cut shares of Xylem from a “hold (c+)” rating to a “hold (c)” rating in a report on Friday, May 8th. Oppenheimer decreased their target price on Xylem from $160.00 to $158.00 and set an “outperform” rating for the company in a research report on Wednesday, April 29th. Stifel Nicolaus cut their target price on shares of Xylem from $163.00 to $159.00 and set a “buy” rating for the company in a research report on Wednesday, April 29th. Citigroup reduced their target price on shares of Xylem from $174.00 to $168.00 and set a “buy” rating for the company in a report on Wednesday, April 29th. Finally, Barclays lowered their price objective on Xylem from $156.00 to $154.00 and set an “overweight” rating on the stock in a research report on Wednesday, April 29th. Eight analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $153.54.

About Xylem

Xylem Inc (NYSE: XYL) is a global water technology company that designs, manufactures and services engineered systems and equipment for the transport, treatment, testing and efficient use of water. Its product portfolio spans pumps and pumping systems, valves, filtration and disinfection equipment, sensors and analytical instruments, and digital solutions for monitoring and control of water infrastructure. Xylem serves the full water cycle with offerings for water and wastewater utilities, industrial customers, commercial and residential buildings, and agricultural applications.

The company was established as an independent publicly traded company in 2011 following a corporate spin-off from ITT Corporation and is headquartered in Rye Brook, New York.